Evelo Biosciences

Cambridge, United States Founded: 2015 • Age: 11 yrs Listed
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.

About Evelo Biosciences

Evelo Biosciences is a publicly listed company based in Cambridge (United States) founded in 2015. Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. Evelo Biosciences has raised $166.5 million across 4 funding rounds from investors including Flagship Pioneering, Celgene and Google Ventures. Evelo Biosciences has completed 1 acquisition, including Epiva Therapeutics. Its chief executive, as recorded, is Simba Gill. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is EVELO BIOSCIENCES, INC. Its competitors include Ironwood Pharma, Alcresta and Seed; 3 of its 3 listed competitors have raised funding.

Company details

Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.

  • Headquarters Cambridge, United States
  • Stage Public
  • Sectors
    Healthcare
  • Website evelobio.com
  • Social LinkedIn X
  • Legal Name Evelo Biosciences, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$114.53 M (USD)
    6.26
    as on Dec 31, 2022
  • EBITDA
    -$103.51 M (USD)
    7.03
    as on Dec 31, 2022
  • Total Equity Funding
    $166.5M (USD)

    in 4 rounds

  • Latest Funding Round
    $25.5M (USD), Post-IPO

    Jul 2023

  • Investors
  • Investments & Acquisitions

Funding Insights of Evelo Biosciences

Evelo Biosciences has successfully raised a total of $166.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.5 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $166.5M
  • Total Rounds 4
  • Last Round Post-IPO β€” $25.5M
  • First Round $35M

    (Nov 2015)

  • Investors Count 5

All 4 funding rounds of Evelo Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2023$25.5MPost-IPO––
Mar 2018$81.5MSeries C––
–
Jul 2017$50MSeries B–Flagship Pioneering, Google Ventures
–
Nov 2015$35MSeries A––
Valuation history

5 investors in total: 5 institutional.

Investors in Evelo Biosciences

Evelo Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Flagship Pioneering, Celgene and Google Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Life sciences-focused venture capital firm
1999flagshippioneering.comCambridge, United States
Corporate backed venture capital fund investing in multiple sectors
gv.comMountain View, United States
Early stage investments focused VC firm
acks.com
Therapies for cancer and inflammatory diseases are developed.
1986celgene.comSummit, United States
ventures.mayoclinic.org
Premium access

Investor details for Evelo Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Evelo Biosciences

20 people are tracked at Evelo Biosciences (6 in leadership, 7 in board & advisors, 7 in team).

NameRoleGroup
Simba Gill
CEOLeadership
Andrea Itano
Head, ResearchLeadership
Aylwin Ng
Head of Systems ImmunologyLeadership
Jonathan Zhung
Chief Development OfficerLeadership
Daniela Walker
Clinical Operations Lead/associate DirectorLeadership
Maria Sizova
Senior Director MicrobiologyLeadership
Juan Andres
DirectorBoard & advisors
Theodose Melas-Kyriazi
DirectorBoard & advisors
Tonya Williams
DirectorBoard & advisors
Robert L. Rosiello
ChairmanBoard & advisors
Alexander C. Reynolds
DirectorBoard & advisors
Jeffrey R. Moore
DirectorBoard & advisors
Jose-Carlos Gutiérrez-Ramos
DirectorBoard & advisors
Laura Jackson
ScientistTeam
Amrita Bhattacharjee
Senior ScientistTeam
Janae Peel
Data Entry ClerkTeam
Anthony Mannion, Ph.D.
Senior ScientistTeam
Lhakyi L.
Laboratory Operations CoordinatorTeam
Barbara J. Romano
Development OperationsTeam
Brianna MacDonald
Senior AccountantTeam
Premium access

Complete people profiles for Evelo Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Evelo Biosciences

Evelo Biosciences is a publicly listed company on the OTC with ticker symbol EVLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date11 May 2018
  • Listed onNASDAQ: NASDAQ
  • Listed entityEvelo Biosciences, Inc.
  • Exchange sectorHealth technology
  • ISINUS2997342025
  • Share price$0.00 · 2026-10-06
  • Market capitalisation$3,796.56
  • Volume (last session)370

Financials of Evelo Biosciences

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2022-$114.5M-$103.5M
2021-$122.2M-$111.3M
2020-$93.7M-$87.9M
Premium access

Detailed financial statements for Evelo Biosciences

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Evelo Biosciences

Evelo Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epiva Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Microbiome-based therapeutics are developed for autoimmune diseases.
epiva.comCambridge, United States2015Jul 2016β€’β€’β€’β€’
Premium access

Complete acquisition details for Evelo Biosciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Evelo Biosciences

5 dated milestones of Evelo Biosciences across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Evelo Biosciences is founded.
  2. Funding First funding round of $35.0M.
  3. Acquisition Acquires Epiva Therapeutics.
  4. IPO Lists on the stock exchange (IPO).
  5. Funding Latest funding round, Post-IPO, of $25.5M.

Competitors of Evelo Biosciences

Evelo Biosciences has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Alcresta and Seed.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ironwoodpharma.com1998Cambridge, United States$206.25M220
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
alcresta.com2011Newton, United States$95.89M52
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
seed.com2016Los Angeles, United States$40.62M
Synbiotics are developed for simulating the gut microbiome.
Premium access

Detailed competitors of Evelo Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Gastroenterology

3 companies that operate in the same segment as Evelo Biosciences (Gastroenterology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
1998Cambridge, Massachusetts, United StatesUSD 206.25 MUSD 296.15 M253
Sacral neuromodulation devices are developed for urinary and bowel control.
2013Irvine, California, United StatesUSD 143.47 M
Provider of a deep learning platform for detecting circulating cancer-related markers
2014United StatesUSD 1.35 B411
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Evelo Biosciences

Premium access

Complete news archive for Evelo Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Evelo Biosciences

Evelo Biosciences was founded in 2015.

Evelo Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Simba Gill is the CEO of Evelo Biosciences, as recorded in our data.

Evelo Biosciences is a funded company, having raised a total of $166.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on Nov 2015.

Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.

Evelo Biosciences's top competitors include Ironwood Pharma, Seed and Alcresta.

Yes, Evelo Biosciences is publicly traded on OTC under the ticker symbol EVLO.

Evelo Biosciences has made 1 acquisition, including Epiva Therapeutics.

Evelo Biosciences has 5 investors. Key investors include Flagship Pioneering, Celgene, Google Ventures, Acks, and Mayo Clinic Ventures.

Evelo Biosciences operates through Evelo Biosciences, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available